Li Lanjuan (1947.9-) female, from Xialuqiao Village, Xialu Town, Shaoxing County, Zhejiang Province. Han nationality, infectious disease expert, academician of the Chinese Academy of Engineering, national key subject leader in infectious diseases, director of the Key Laboratory of Infectious Diseases of the Ministry of Health, pioneer of artificial liver in my country, former director of the Zhejiang Provincial Department of Health, director of the Key Laboratory of Infectious Diseases of the Ministry of Health , professor, chief physician, doctoral supervisor, executive director of the Chinese Women Physicians Association, director of the Chinese Medical Association, president of the Zhejiang Branch of the Chinese Medical Association, vice president of the Chinese Medical Association, deputy director of the Infectious Diseases Branch of the Chinese Medical Association, China Vice chairman of the Microecology Branch of the Society of Preventive Medicine and leader of the Liver Failure and Artificial Liver Science Group. Chief editor of the national medical planning textbook "Infectious Diseases" in colleges and universities, chief editor of the Journal of Infectious Diseases, and deputy editor of the Infectious Diseases Division of Chinese Infectious Diseases and Foreign Medical Epidemiology. Director of the National Artificial Liver Training Base. In 2005, he was elected as an academician of the Chinese Academy of Engineering.
Li Lanjuan graduated from the Department of Medicine of Zhejiang Medical University in 1973. She has been engaged in infectious disease medical treatment, teaching and research for more than 30 years and has made remarkable achievements. In March 2013, Chinese scientists led by Academician Li Lanjuan made a major breakthrough in H7N9 avian influenza research. The paper "Human Infection with New H7N9 Subtype Avian Influenza Viruses Sourced from the Live Poultry Market: Clinical Analysis and Viral Genome Characteristics" has been published in the world The famous medical journal "The Lancet" published it online.
A major breakthrough was achieved in creating a unique and effective artificial liver support system to treat severe hepatitis (ALSS). The mortality rate of acute and subacute severe liver disease has been significantly reduced from 88.1% to 21.1%, and the mortality rate of chronic severe liver disease has been reduced from 84.6% to 56.6%. More than 700 cases have been treated. Presided over the formulation of ALSS technical specifications as national standards and actively promoted them nationwide; won the second prize of the National Science and Technology Progress Award. Established my country's first immortalized human liver cell line; created a new four-step perfusion method to isolate liver cells; and constructed a new hybrid artificial liver. Applied for 9 patents, 2 of which have been authorized. For the first time, he revealed the changes in the intestinal microecology of patients with severe liver disease and proposed the B/E value as a new indicator of intestinal colonization resistance. He discovered five new beta-lactamase genotypes and won the first prize of the Provincial Science and Technology Progress Award in 2001 and 2003 respectively. He has published more than 130 papers, and more than 10 papers have been included in SCI. He has edited 8 monographs and co-edited 9 books.